GePharm

What GePharm does

GePharm is a privately held, founder-owned Turkish pharmaceutical company founded in 2010 that develops and supplies products and consulting services focused on rare diseases, with phenylketonuria (PKU) as its lead therapeutic area. The company markets two product families — Callion, targeted at patient needs for rare and metabolic diseases, and Veriton, designed for healthcare-professional-supervised use — and sells Avonil, a phenylalanine-free amino acid formula for PKU dietary management available in 500g powder and tablet forms. GePharm operates through a sales-led go-to-market, engaging physicians, dietitians, and metabolic specialists via regional representatives, and is supported by a wholly owned Canadian subsidiary (GePharm Canada Inc., established 2014 in Toronto) that anchors international collaboration. The company monetizes through direct sales of specialized medical foods and pharmaceutical products under the Callion and Veriton brands, while also offering consulting services in regulatory affairs, clinical research, market access, and business development to other national and international pharma firms. GePharm positions itself as a regulatory and market access partner for rare disease therapies in Turkey, with an active multilingual website (Turkish, English, French), a healthcare-professional portal with pharmacovigilance reporting, and patient education resources for PKU.

Name

GePharm

Legal name

GePharm İlaç San. ve Tic. Ltd. Şti.

Website

https://gepharm.com.tr

Company type

Private

Founded year

2010

Operating status

Operating

Headcount range

1–10 employees

Short description

GePharm is a Turkish pharmaceutical company founded in 2010 that develops and distributes specialty medical foods and consulting services for rare diseases, primarily phenylketonuria (PKU), serving patients, healthcare professionals, and pharma partners in Turkey and Canada.

Ownership category

akta.pro rank

Product category

Specialty Pharmaceuticals — Rare Disease Nutrition

NAICS

Pharmaceutical Preparation Manufacturing (325412), Medicinal and Botanical Manufacturing (325411)

SIC

Medicinal Chemicals & Botanical Products (2833)

akta.pro primary industry

Rare Pediatric & Congenital Disorder Therapies (HLAIAIAN)

akta.pro secondary industries

Endocrinology & Metabolic Specialty Pharmaceuticals (HLAIACAD), Genetic & Genomic Rare Disease Therapeutics (HLAIAIAA)

Keywords

• Rare disease pharmaceuticals
• Phenylketonuria management
• Medical foods
• Specialty pharma consulting
• Metabolic disorder treatments

Headquarters

HQ city

Istanbul

HQ country

Türkiye

HQ region

Europe

Offices2 records

Markets served

GTM type

B2B and B2C

Offering type

Hardware or Manufacturing

Cost components

Supply Chain, Personnel, Operations, Marketing or Sales, Technology or R&D

Revenue model

1. Pharmaceutical Product Sales: GePharm generates revenue through the sale of specialized pharmaceutical products for rare diseases, including the Callion and Veriton product families. The Callion family targets rare disease patients directly, while Veriton serves healthcare professionals' supervision needs. Products include Avonil, a phenylalanine-free amino acid formula for PKU management sold in powder and tablet forms.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

Core offering

GePharm develops, manufactures, and supplies pharmaceutical products for rare diseases with a primary focus on phenylketonuria (PKU). The company sells two product families — Callion (patient-centered formulations for rare diseases) and Veriton (quality-focused support products for healthcare professional supervision) — including Avonil, a phenylalanine-free amino acid formula available in powder and tablet forms. Beyond product sales, GePharm provides consulting services to national and international pharmaceutical companies covering regulatory affairs, clinical research, market access, and business development.

Product overview

GePharm is a patient-focused pharmaceutical company that offers two product families — Callion and Veriton — addressing rare diseases and special treatment areas. Callion is a patient-centered product family targeting rare diseases and metabolic conditions (including PKU), while Veriton provides quality-focused support products for healthcare professional-supervised use. A specific product under Callion is Avonil, a phenylalanine-free amino acid formula for PKU dietary management available in powder and tablet forms. All products are managed according to international quality standards and evidence-based principles.

Differentiator

Problem solved

Functional benefit

Brands

• Callion: Product family for rare diseases and special treatment areas, centered on patient needs.
• Veriton
• Avonil

Products and services

• Avonil Avonil is a phenylalanine-free, amino-acid-based food for special medical purposes used in the dietary management of phenylketonuria (PKU). Available in 500g powder and tablet forms, Avonil is formulated to meet the nutritional needs of PKU patients while maintaining blood phenylalanine within safe ranges. The product is part of GePharm's Callion product family and is offered for use under specialist supervision.
• Callion Product Family Callion is a patient-centered product family developed for rare diseases and special treatment areas, including metabolic diseases such as PKU. Formulations are designed with focus on taste, ease of use, and treatment adherence to support patients' lifelong dietary management needs. Products under the Callion family include Avonil, a phenylalanine-free amino acid formula.
• Veriton Product Family Veriton is a quality-focused product family of support products designed for use under the supervision of healthcare professionals. Produced in GMP-compliant facilities, Veriton products offer standardized content and dosing for predictable, standards-compliant therapeutic options that support clinical treatment processes for rare diseases.
• Pharmaceutical Consulting Services End-to-end consulting services provided by GePharm to national and international pharmaceutical companies, covering regulatory affairs, clinical research, market access, and business development. These services help pharmaceutical partners bring rare disease treatments and orphan drugs to the Turkish market.

Quantifiable outcome

• 100% specialist supervision for patient care
• +1 more outcomes

Segments3 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Scale indicators5 records

Recent moves7 records

Expansion highlights5 records

Broad incumbents

• Nestlé Health Science: Operates a medical nutrition business that includes products for PKU and other inborn errors of metabolism. Comparable as a multinational manufacturer of medical foods for rare metabolic conditions.
• Swedish Orphan Biovitrum (Sobi): Global rare disease biopharmaceutical company with a presence in metabolic and genetic disorders. Comparable as a larger, established player commercializing orphan therapies across multiple geographies.
• Mead Johnson (Reckitt): Major infant nutrition and metabolic medical foods business (Reckitt), offering PKU formulas alongside a broad nutrition portfolio. Comparable as a larger incumbent in phenylalanine-free medical nutrition.
• Recordati Rare Diseases: Specialty pharma division of Recordati Group focused on rare and orphan diseases, including metabolic conditions. Comparable as an established rare disease commercializer with broader geographic reach.
• Alexion / AstraZeneca Rare Disease: Global rare disease biopharmaceutical group (now part of AstraZeneca) operating across metabolic, genetic, and other orphan indications. Comparable as a broad incumbent with deep rare disease commercialization expertise.

Direct peers

• BioMarin Pharmaceutical: Global leader in PKU therapies (Kuvan, Palynziq) and rare disease drug development. Directly comparable as a rare disease specialty pharma targeting the same PKU patient population GePharm serves.
• Danone Nutricia: Operates a major metabolic disease medical food business including PKU formulas (e.g., Anamix, Lophlex). Comparable as a manufacturer and distributor of phenylalanine-free amino acid products for PKU dietary management.
• Vitaflo: International medical nutrition company specializing in PKU and other inherited metabolic disorders, offering amino acid-based foods for special medical purposes. Closely mirrors GePharm's Avonil product positioning.
• Cambrooke Therapeutics: US-based company focused on medical foods and pharmaceutical-grade therapies for PKU and other rare metabolic disorders. Directly comparable niche player in phenylalanine-free nutrition.

Emerging players

• Promin Metabolics: UK-based specialist provider of low-protein foods and PKU dietary products. Comparable as a niche player in metabolic disease nutrition with overlapping customer base to GePharm's Callion family.

Market position

Strengths4 records

Weaknesses5 records

Competitive moat3 records

Key risks6 records

Key highlights6 records

Customer concentration

• Facebookfacebook.com/gepharmltd
• LinkedInlinkedin.com/company/gepharm

Revenue estimate

Valuation estimate

Number of profiles

Profiles3 records

Subsidiaries1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about GePharm